about
European guidance for the diagnosis and management of osteoporosis in postmenopausal womenOsteoporosis and sarcopenia in older ageA systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.Correlation between osteoporotic fracture risk in Brazilian postmenopausal women calculated using the FRAX with and without the inclusion of bone densitometry data.UK clinical guideline for the prevention and treatment of osteoporosisEvaluating osteoporotic fracture risk with the Fracture Risk Assessment Tool in Chinese patients with rheumatoid arthritis.Are we taking full advantage of the growing number of pharmacological treatment options for osteoporosis?Pre-screening young postmenopausal women for BMD testing.Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fracturesPrevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014.How many high risk korean patients with osteopenia could overlook treatment eligibility?Recommendations for evaluation and management of bone disease in HIV.Management of severe osteoporosis.Bone Density Screening and Re-screening in Postmenopausal Women and Older Men.Rapid screening for sarcopeniaFortification of Yogurts with Vitamin D and Calcium Enhances the Inhibition of Serum Parathyroid Hormone and Bone Resorption Markers: A Double Blind Randomized Controlled Trial in Women over 60 Living in a Community Dwelling HomeFracture Rates and Bone Density Among Postmenopausal Veteran and Non-Veteran Women From the Women's Health Initiative.SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes.Polarization control of Raman spectroscopy optimizes the assessment of bone tissueHealth technology assessment in osteoporosis.Commentary on guidelines on postmenopausal osteoporosis - Indian Menopause Society.Diagnostic criteria for osteoporosis should be expandedFracture risk assessment in postmenopausal women referred to an Italian center for osteoporosis: a single day experience in Messina.A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.Type 2 diabetes and bone.Management of cancer treatment-induced bone loss.Comparison between various fracture risk assessment tools.Agreement between FRAX scores calculated with and without bone mineral density in women with osteopenia in Turkey.Challenges for the development of bone-forming agents in Europe.Pharmacologic Options for the Treatment of Sarcopenia.Bone Disease in HIV: Recommendations for Screening and Management in the Older Patient.Swedish osteoporosis care.Self-perception of fracture risk: what can it tell us?FRAX and fracture prediction without bone mineral density.SIGN Guidelines for Scotland: BMD Versus FRAX Versus QFracture.Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative.Hyponatremia and fractures: should hyponatremia be further studied as a potential biochemical risk factor to be included in FRAX algorithms?FRAX- vs. T-score-based intervention thresholds for osteoporosis.Overview of Fracture Prediction Tools.Vertebral fracture in postmenopausal Chinese women: a population-based study.
P2860
Q24612411-FCBC7F82-9A0D-4922-81CF-C36759FB7004Q28081106-0DDC0454-650F-4154-90BF-3EE18AD3945AQ30248756-763ED001-74AA-42F3-BE57-15F5D9291828Q31074076-D460291F-69AF-47AA-98E8-FBA04534371AQ33581078-02E9F9D7-7DDE-40B8-A852-4FF8D9605B48Q33644108-3CE77CDA-38BF-48B9-9F57-46F7E927A1FBQ33811677-BC480FBC-D90C-49F1-8439-115DD4CEBC5DQ33833419-74473749-B4F6-4824-AC2B-89D1DF8CEB92Q34084507-E407F458-0219-47EC-9C1B-AD2F86A84752Q34591010-F9F80D7B-441D-4CC5-B742-C993326A66DDQ34785178-72A75991-78D0-4CC1-9F07-A5F699305757Q35451868-D3321A52-A042-4D49-93B8-D9F5A181CF5AQ35852252-86D78269-E8D4-45CA-A38A-91B74CF47C30Q36217631-91AA2199-1CAC-4B4A-AC3E-760720C04C67Q36349343-E671E810-2CEA-4C79-8F3D-A3900F9CB95BQ36378579-45A8BA8E-8058-44DC-BC36-2D40B9C6ACAFQ36595912-0876D2DF-516B-410C-AB43-8E675FEE7483Q36706584-E5B02210-5B59-4AE6-BE2E-E21CDB09DC97Q36872141-8B2934C7-5583-4C79-91F7-F6AF01B25965Q36965411-004097CD-0CEF-4773-B4A9-FF8553DDC5FEQ37202409-73D99A85-5A7D-44DB-BD87-2A52EBC5F900Q37392401-CED0D6B9-56E0-4C6A-9A90-D5E1F2896A6BQ37567203-1C52E92B-12C6-48B1-9F86-B0E80C5CCC41Q37995500-8B778309-2212-4E82-9D3A-CAB8E3204471Q38048186-5E963EBF-3B5D-4216-AC2B-A03B0CB4F4CEQ38090917-6C742A64-A25F-4FD2-8B82-45A52D28C611Q38116795-33FA208C-5179-4736-A9C6-9362B9732A26Q38182882-7B9DBC39-E6A7-4D25-A9C7-FFB39B4C0314Q38200945-10B752D2-E30D-4A22-896C-E1298AC596FEQ38534875-8B440798-A0AB-4425-B73D-2D40FF469C99Q38540406-BCA87C18-DDAD-44D2-8DB0-612A8408B405Q38563886-08BF20FE-CD1B-4190-B92F-7A4F66D8885CQ38598416-BA8FBA25-38AC-494A-A1E9-4DD6443B683AQ38613173-46DD5E28-AC67-471D-B060-8175A962CEEEQ38664026-F246DCFC-C672-4609-AA40-42269C104612Q38757607-9E97F2CD-3E10-457E-BF2F-61AC9A7B48B6Q39028073-C5522C50-C55C-48B1-8A02-84ADCB9CB0F9Q40092757-80681D85-A61D-4BBB-8861-8DB50AA6DB4CQ40119539-1BCA18A9-EDD1-475D-A12C-CFD986141346Q40179679-D1FB8F4C-4F77-4756-9905-DBA1CA835263
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
FRAX
@nl
FRAX(®) with and without bone mineral density.
@en
type
label
FRAX
@nl
FRAX(®) with and without bone mineral density.
@en
prefLabel
FRAX
@nl
FRAX(®) with and without bone mineral density.
@en
P2093
P2860
P1476
FRAX(®) with and without bone mineral density.
@en
P2093
Anders Oden
Eugene McCloskey
Helena Johansson
John A Kanis
P2860
P2888
P356
10.1007/S00223-011-9544-7
P407
P577
2011-11-06T00:00:00Z